NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PATH EX, Inc.

PATH EX, Inc.

Private
Houston, TexasHealthcare & Life Scienceshttps://pathex.co/

Last Round

Series A

Apr 25, 2025

Total Funding Raised

$6.88M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

PATH EX, Inc. is a medical device company developing CycloPE®, a blood purification device designed to directly capture and remove bacteria from the bloodstream to treat sepsis.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

sepsis treatmentextracorporeal blood cleansingblood purificationmedical devicepathogen removalendotoxin removalblood filtrationbacteremia treatmentcritical care technologymicrobial identificationblood dialysissepsis managementFDA breakthrough device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PATH EX, Inc. Comparables

Compare PATH EX, Inc. with similar companies based on industry and business-model similarity.

PATH EX, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

PATH EX, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 25, 2025
GrantSep 23, 2021
SeedOct 1, 2020
GrantJun 1, 2018
GrantJul 1, 2017

Key People

Founding team and executive leadership

Sinead E. Miller

CEO And Cofounder

Founding Team

Alex Wieseler

COO

Executive Team

PATH EX, Inc. Investors

Notable investors and investment history

PATH EX, Inc. investors
InvestorRounds
MedTech InnovatorGrant
IAG Capital PartnersSeries A
ZeroTo510Accelerator
MassChallengeSeed
Texas Medical CenterSeries A
AdvaMed AccelGrant
Fitz Gate VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Monthly visitors increased 152% MoM, reaching 1K.

  • Jun 1, 2018

    Received $910K from the National Science Foundation.

PATH EX, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PATH EX, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PATH EX, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHouston, Texas
Employee Range9
Year Founded2017
Last FundingApr 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.